{
    "clinical_study": {
        "@rank": "36846", 
        "arm_group": {
            "arm_group_label": "Intrathecal autologous stem cells", 
            "arm_group_type": "Experimental", 
            "description": "Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria."
        }, 
        "brief_summary": {
            "textblock": "Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the\n      neurodegenerative process and stops the clinical progression of disease."
        }, 
        "brief_title": "Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Amyotrophic Lateral Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Amyotrophic Lateral Sclerosis", 
                "Sclerosis", 
                "Motor Neuron Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "There is no more extensive information"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with a confirmed diagnosis of ALS according to El Escorial criteria.\n             Diagnosis-time less than four years.\n\n          -  Over 18 years old. Forced vital capacity \u2265 40%.\n\n          -  One year of evolution.\n\n          -  Adequate nutritional state\n\n        Exclusion Criteria:\n\n          -  Severe bulbar ALS involucre.\n\n          -  Inadequate nutritional status.\n\n          -  Spondylotic myelopathy, or abnormalities in imaging study.\n\n          -  Having concomitant neurological or psychiatric disease.\n\n          -  Systemic disease with poor-control.\n\n          -  History of treatment with steroids or immunoglobulins in the last year.\n\n          -  Participate in the past three months in a Clinical Trial.\n\n          -  History of malignancy or cancer today.\n\n          -  Intracranial hypertension.\n\n          -  Clinical suggestive data of infection in the site of lumbar puncture.\n\n          -  Tracheostomy.\n\n          -  Use of mechanical ventilation. Forced vital capacity less than 40%. HIV-seropositive\n             or presence of antibodies against hepatitis B or C in the serological studies."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933321", 
            "org_study_id": "ALS and stem cell therapy"
        }, 
        "intervention": {
            "arm_group_label": "Intrathecal autologous stem cells", 
            "description": "Mobilization and collection of stem cells for intravenous and intrathecal administration", 
            "intervention_name": "Intrathecal autologous stem cell", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ALS, stem cells", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Monterrey", 
                    "country": "Mexico", 
                    "state": "Nuevo Le\u00f3n", 
                    "zip": "64460"
                }, 
                "name": "Servicio Hematolog\u00eda Hospital Universitario"
            }
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)", 
        "overall_official": [
            {
                "affiliation": "Hospital Universitario \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\"", 
                "last_name": "David Gomez-Almaguer, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\"", 
                "last_name": "Jose C Jaime-P\u00e9rez, MD PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hospital Universitario \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\"", 
                "last_name": "H\u00e9ctor R Mart\u00ednez-Rodr\u00edguez, MD PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Mexico: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of autologous intrathecal administration of hematopoietic stem cells in patients with ALS.", 
            "safety_issue": "Yes", 
            "time_frame": "up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933321"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario Dr. Jose E. Gonzalez", 
            "investigator_full_name": "David Gomez Almaguer", 
            "investigator_title": "Chair of Hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the safety of intrathecal administration of hematopoietic stem cells in patients with ALS.", 
            "safety_issue": "Yes", 
            "time_frame": "During the procedure and at 1st, 2nd, 3rd, 6th and 12 th month after the procedure"
        }, 
        "source": "Hospital Universitario Dr. Jose E. Gonzalez", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario Dr. Jose E. Gonzalez", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}